

New Insights into Low Dose Dexamethasone Suppression Test in Paediatric Cushing's Syndrome (CS)

Ingrid CE Wilkinson¹, Lee Martin², Ashley B Grossman^{1,3}, John P Monson¹, Scott Akker¹, Martin O Savage¹, William M Drake¹ and Helen L Storr¹
 1. Centre for Endocrinology, William Harvey Research Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, First Floor, John Vane Science Centre, Charterhouse Square, London, UK
 2. Department of Paediatric Endocrinology, Royal London Hospital, Whitechapel Road, Whitechapel, London, UK
 3. Oxford Centre for Diabetes, Endocrinology and Metabolism, University of Oxford, Oxford, OX3 7LJ, UK

Introduction:

The Low dose dexamethasone suppression test (LDDST) is an important investigation for suspected Cushing's Syndrome (CS). The traditional definition of normal suppression of serum cortisol to ≤ 50 nmol/L during the LDDST (0.5 mg 6 hrly x 48 hrs) comes from a time when biochemical autoanalysers did not routinely detect very low values. Previous studies reported 5.1-8.3% of patients with Cushing's Disease (CD) suppressed to < 50 nmol/L at 48 hrs during LDDST. Many clinicians experienced in the assessment of suspected CS consider that 'normal' individuals should suppress to ≤ 20 nmol/L during a LDDST and that LDDST values of 20-50 nmol/L represent a range of uncertainty. Current sensitivity and specificity is reported as 90% and 100% for a cut off of ≤ 50 nmol/L.

Methods:

We reviewed a retrospective cohort of paediatric patients referred to our centre with suspected CS between 1982 and 2018.

Results:

Of 84 suspected CS patients, 50 had Cushing's Disease (CD), 8 had Primary Pigmented Nodular Adrenocortical Disease (PPNAD) and 26 'control' subjects, in whom the diagnosis of CS was excluded following detailed biochemical evaluation and prolonged clinical/auxological follow-up. The patient characteristics are summarised in table 1.

Table 1. Patient characteristics in the different diagnostic groups

Patient Group	CD	PPNAD	Controls	Total for all groups
Patients, n	50	8	26	82
Males	29	4	5	38
Mean age, years	12.4	12.9	12.3	12.3
Standard Deviation	3.4	2.2	4.3	3.6
Range	5.6-17.8	10.5-16.9	4.3-17	4.3-17.8

The serum cortisol remained > 50 nmol/l in 44/50 (88%) CD patients (29 males, median age 13.31 years) during LDDST. In contrast, cortisol during LDDST was > 20 nmol/l in 49/50 (98%) CD patients. One patient with cortisol ≤ 20 nmol/L during LDDST had a high clinical suspicion of CD and investigations including bilateral simultaneous inferior petrosal sinus sampling confirmed this.

Figure 1 summarises the mean cortisol values at the start of the LDDST, whereas figure 2 summarises the mean cortisol values post LDDST in each of the groups. The sensitivity and specificity of a LDDST cut off value of ≤ 20 nmol/l is 98% (95% confidence interval 89.4-100%) and 96% (80.4-99.9%). None of the 8 PPNAD patients (4 male, median age 12.5 years, range 10.5-16.9) had cortisol levels of ≤ 50 nmol/l during LDDST. Cortisol levels in 25/26 controls (5 males, median age 14 years, range 4.3-17.0) suppressed to ≤ 20 nmol/l during LDDST. In one other patient with a diagnosis of mosaic turners syndrome, high androgens, hypertension and obesity, the cortisol suppressed to 22 nmol/l.

Figure 1. Pre LDDST mean cortisol levels (nmol/l) in each group





Figure 2. Post LDDST mean cortisol levels (nmol/l) in each group



Conclusion:

Whilst the numbers are small, changing the LDDST cut off from ≤ 50 nmol/L to ≤ 20 nmol/L improves the sensitivity of the test from 85.71% to 97.96% in our paediatric CD patients. This does not adversely affect the specificity which remains 100%. We therefore suggest using serum cortisol of ≤ 20 nmol/l as a new diagnostic cut off value.

William Harvey Research Institute